Categories AlphaGraphs, Earnings, Technology

INTC Infographic: Intel Q2 2023 revenues and adjusted earnings fall

Semiconductor giant Intel Corporation (NASDAQ: INTC) Thursday reported lower adjusted net income and revenues for the second quarter of 2023.

Intel Q2 2023 earnings infographic

Revenues plunged 15% year-over-year to $12.9 billion in the second quarter. Client Computing and Data Center & AI Group, the company’s main operating segments, contracted sharply during the three-month period.

The tech firm reported earnings of $0.13 per share for the June quarter, on an adjusted basis, compared to $0.28 per share in the second quarter of 2022. On a reported basis, net income was $1.5 billion or $0.35 per share, compared to a loss of $0.5 billion or $0.11 per share last year.

“Our Q2 results exceeded the high end of our guidance as we continue to execute on our strategic priorities,
including building momentum with our foundry business and delivering on our product and process roadmaps,” said Intel’s CEO Pat Gelsinger.

Prior Performance

  • Intel Q4 2022 earnings infographic
  • Intel Q3 2022 earnings infographic
  • Intel Q2 2022 earnings infographic


Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock


Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight